Zaks, fresh from making millions at Moderna, takes venture partner post at OrbiMed Inovio falls victim to AstraZeneca's 'usual pipeline pruning' as human papillomavirus cancer vaccine deal axed Cytokines claimed spotlight due to COVID-19. Now, Merck will work with Synthekine to understand their role in autoimmune disorders Sponsored: A New Reference Model for Clinical Trial Recruitment, Enrollment and Retention Success LianBio snags $325M IPO, slightly bigger than the multi-partnered biotech's 2020 series A Sponsored: Intranasals in Clinic Now Positioned for $71 Billion Nasal Delivery Market Gilead bought his last biotech. Now, Helin is back with another cancer startup Lengo's hiring spree shows no signs of slowing as it hires Pfizer veteran Murray as VP of research Fierce Healthcare's 2021 Women of Influence Awards MIT team uncovers differences in T cells that drive immuno-oncology resistance in lung cancer Novartis keeps the leukemia innovation coming with FDA approval for Gleevec follow-on Scemblix as Tasigna patent cliff nears BD inks BARDA contract to develop COVID tests for the long future of the pandemic Featured Story | By Nick Paul Taylor Tal Zaks has revealed his next job. Weeks after leaving Moderna, Zaks has taken up a venture partner post at OrbiMed—where he is joined by another storied biopharma executive. read more |
| |
|---|
|
Top Stories By Annalee Armstrong AstraZeneca is wielding the ax to a bloated pipeline and Inovio has found itself the latest victim. MedImmune, an AstraZeneca unit, has terminated a collaboration agreement with Inovio for the cancer immunotherapy MEDI0457, which was being developed to target cancers caused by certain types of the human papillomavirus. read more By Kyle LaHucik The world got a little more steeped in cytokine knowledge because of the small protein's role in COVID-19, and, now, Merck will study how they work in autoimmune diseases through a $525 million biobucks deal with Synthekine. read more Sponsored by: IPM.ai Rare diseases demand a modern recruitment approach grounded in uncovering the ideal, medically-eligible patient population with the highest propensity for study enrollment and retention. read more By Kyle LaHucik Partner-heavy biotech LianBio secured $325 million in its Wall Street debut to fund a series of trials across cardiovascular, oncology, ophthalmology, inflammatory and respiratory diseases. The Shanghai biotech raised $310 million in a series A last year and has lined up partners like Bristol Myers Squibb's MyoKardia, BridgeBio, Tarsus, Lyra and others. read more Sponsored By: Avance Clinical the Australian CRO for global biotechs Australia’s Avance Clinical: how intranasal biotechs can expedite trials with rapid approval processes - including no IND and a 43.5% incentive rebate - to tap $71 billion market read more By Nick Paul Taylor The founder of a biotech bought by Gilead has birthed another startup. Dania Therapeutics begins life with a discovery program based on Kristian Helin’s work and plans to advance small-molecule inhibitors of new oncology targets. read more By Ben Adams Lengo Therapeutics has named a slate of new hires in recent months and is back at it again, nabbing Turning Point’s Brion Murray, Ph.D., as its senior vice president of research. read more By Heather Landi We are honoring leaders who have made a measurable impact on healthcare in the past year and who have paved the way forward for women and men alike. These leaders epitomize innovation, passion and ingenuity. read more By Arlene Weintraub MIT scientists discovered a subset of T cells that become dysfunctional because of changes in gene expression that occur while they’re being activated in the lymph nodes. They reactivated the T cells in mouse models of non-small cell lung cancer with two cytokines, offering insights into improving responses to immuno-oncology drugs in people, they said. read more By Angus Liu About two decades ago, Novartis transformed leukemia treatment with the introduction of Gleevec. Now, the Swiss pharma has ushered a third-generation therapy targeted against the blood cancer across the regulatory finish line. read more By Conor Hale BD has inked a public-private partnership with the U.S. government to ready its current lines of COVID-19 diagnostics for the long haul of the pandemic—by developing combination tests that simultaneously screen for the flu and other infectious diseases from a single sample. read more | | LabConnect is the leader in innovative central laboratory services for advanced therapies. Far more than typical central laboratory support, only LabConnect offers comprehensive, specialized services customizable to meet the unique needs of your complex clinical trials. Connect with us today. |
Resources Sponsored by: Informa Pharma Intelligence and Oracle Health Sciences New market research provides valuable insight into the impact of adaptations made in clinical trials during the pandemic. Sponsored by: TransPerfect Life Sciences Every detail is important when selecting a new eCOA solution; learn more about the current eCOA landscape, best practices, and crucial considerations for successful eCOA solution deployment in this white paper. Sponsored by: Thermo Fisher Scientific Learn how to develop a high-performing supply chain for cGMP chemicals used throughout your biologics workflow. Download the free whitepaper from Thermo Fisher Scientific Sponsored by: Drexel University Online Drexel University’s online graduate programs in biomedicine, clinical research, drug discovery, and molecular medicine were developed with working professionals in mind, providing you with the education, practical skills, and competitive edge you need to be successful in your career. Learn more. Sponsored by: Oracle Health Sciences New research indicates an accelerated adoption of decentralized clinical trials due to COVID-19. Sponsored by: Box Read Get to Know Cloud Content Management for Life Sciences and learn how to eliminate silos across all workflows, from R&D to commercialization. Pharma Meeting Pros Summit November 3-4, 2021 | Atlantic City, NJ & Virtual Diversity, Equity & Inclusion Summit November 9–10, 2021 | Virtual Event Learn impact of pricing, competitive assessment, epidemiology November 17-18, 2021 | Live & Online Drug Development Boot Camp® 2021 Onsite and VIRTUAL in real time November 17-18, 2021 | Register now! Pre-Boot Camp preparation is now available. New Product Planning Summit December 1-2, 2021 | Boston, MA Launch Readiness for Medical Affairs & Communications Teams December 1-2, 2021 | Boston, MA Learn how therapeutics are successfully launched and commercialized December 1-2, 2021 | Live & Online Virtual Clinical Trials Summit December 6-7, 2021 | Philadelphia, PA Fierce JPM Week 2022 January 11, 2022 | San Francisco, CA
January 18-20, 2022 | Virtual Event Virtual European Healthcare Compliance Certificate Program January 24-28, 2022 Fierce Pharma Drug Safety Summit February 2022 | Location TBD Fierce Biotech Forum 2022 | Virtual Event | 